Drug firms cut doctors’ fees for drug talks

BMJ 2014; 348 doi: (Published 07 March 2014) Cite this as: BMJ 2014;348:g2021
  1. Michael McCarthy
  1. 1Seattle

In the face of new disclosure rules, a number of drug firms in the United States are dramatically reducing their payments to doctors for promotional speeches, an analysis by the non-profit, investigative news organization ProPublica has found.1

The analysis found that Eli Lilly’s payments to speakers dropped by 55%, from $47.9m (£28.6m; €34.5m) in 2011 to $21.6m in 2012. Over the same period …

View Full Text

Log in

Log in through your institution


* For online subscription